You are using an outdated browser. Please upgrade your browser to improve your experience and security.

The FDA approval of VYXEOS (CPX-351) was based on data from a large, pivotal, Phase 3 study1

The Phase 3 study was a multicenter, open-label, active-controlled, randomized trial of VYXEOS vs 7+3a in 309 patients (aged 60-75) with newly-diagnosed t-AML or AML-MRC2

VYXEOS was studied in older patients with newly-diagnosed sAML who often face a poor prognosis1,2,6

View more information about t-AML and AML-MRC

sAML patient characteristics in the Phase 3 study

All patients in the Phase 3 study had difficult-to-treat sAML1,2

41% of patients treated with VYXEOS had prior HMA exposure1

For patients >60 years old with AML, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend selecting a treatment option based on patient performance status, comorbid conditions, and adverse features such as subtype rather than chronologic age alone9

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.